Affordable Prescriptions for Patients Act of 2019
Latest action · Jun 28, 2019 Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMay 9, 2019
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Affordable Prescriptions for Patients Act of 2019
This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer’s already-approved drug or biological product that still treats the same medical condition.
A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.
A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.
This bill also limits the number of patents that may be included in infringement claims brought by approved biological product license holders against applicants for a biosimilar product license.
Cosponsors 13
Members who signed on, in the order they did. Signatures ran from May 9, 2019 to Nov 21, 2019; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CT | Richard Blumenthal | Original | May 9, 2019 |
| R-WV | Shelley Moore Capito | May 15, 2019 | |
| D-WA | Patty Murray | May 22, 2019 | |
| R-LA | John Kennedy | Jun 3, 2019 | |
| R-FL | Rick Scott | Jun 3, 2019 | |
| R-MO | Josh Hawley | Jun 4, 2019 | |
| D-IL | Richard J. Durbin | Jun 26, 2019 | |
| I-ME | Angus S. King Jr. | Jul 24, 2019 | |
| D-MN | Tina Smith | Sep 12, 2019 | |
| D-MI | Gary C. Peters | Sep 25, 2019 | |
| R-NE | Deb Fischer | Nov 13, 2019 | |
| R-AZ | Martha McSally | Nov 13, 2019 | |
| R-PA | Patrick J. Toomey | Nov 21, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Judiciary Committee | Referred May 9, 2019Markup Jun 27, 2019Reported Jun 28, 2019 |
Actions 5
Everything that happened, newest first.
- Jun 28, 2019Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.
- Jun 28, 2019Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
- Jun 27, 2019Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
- May 9, 2019Introduced in Senate
- May 9, 2019Read twice and referred to the Committee on the Judiciary.
In the Congressional Record 18
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| Senate | Debate and remarks S7127 | John Cornyn R-TX | Dec 1, 2020 |
| Senate | Debate and remarks S1099 | John Cornyn R-TX | Feb 24, 2020 |
| Senate | Debate and remarks S71 | John Cornyn R-TX | Jan 8, 2020 |
| Senate | Debate and remarks S6967, S6968 | Charles E. Schumer D-NY, John Cornyn R-TX | Dec 11, 2019 |
| Senate | Debate and remarks S6742 | John Cornyn R-TX | Nov 21, 2019 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Congressional Budget Office cost estimate
- Jul 19, 2019S. 1416, Affordable Prescriptions for Patients Act of 2019As reported by the Senate Committee on the Judiciary on June 28, 2019
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
| R46221 | Drug Pricing and Pharmaceutical Patenting Practices Archived | Report | Feb 11, 2020 |
Related bills 3
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 3991 | Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 | Related bill | Nov 21, 2019 |
| HR 4398 | Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 | Related bill | Oct 2, 2019 |
| HR 5133 | Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 | Related bill | Dec 24, 2020 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
- Short Title(s) as Introduced
- Affordable Prescriptions for Patients Act of 2019
- Short Title(s) as Reported to Senate
- Affordable Prescriptions for Patients Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Commerce.
- Administrative remedies
- Civil actions and liability
- Commerce
- Competition and antitrust
- Consumer affairs
- Drug safety, medical device, and laboratory regulation
- Federal Trade Commission (FTC)
- Health care costs and insurance
- Inflation and prices
- Intellectual property
- Judicial review and appeals
- Manufacturing
- Prescription drugs
Text 2
Each version as it was printed, newest first.
- Jun 28, 2019Reported to Senate
- May 9, 2019Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.